AR009066A1 - Composicion formulada con contenido de insulina - Google Patents
Composicion formulada con contenido de insulinaInfo
- Publication number
- AR009066A1 AR009066A1 ARP970103667A ARP970103667A AR009066A1 AR 009066 A1 AR009066 A1 AR 009066A1 AR P970103667 A ARP970103667 A AR P970103667A AR P970103667 A ARP970103667 A AR P970103667A AR 009066 A1 AR009066 A1 AR 009066A1
- Authority
- AR
- Argentina
- Prior art keywords
- nph insulin
- igf
- insulin
- composition formulated
- insulin content
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
- 102000004877 Insulin Human genes 0.000 title 1
- 108090001061 Insulin Proteins 0.000 title 1
- 229940125396 insulin Drugs 0.000 title 1
- 102000005237 Isophane Insulin Human genes 0.000 abstract 6
- 108010081368 Isophane Insulin Proteins 0.000 abstract 6
- LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 abstract 6
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 4
- 238000009472 formulation Methods 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 1
- 125000000218 acetic acid group Chemical class C(C)(=O)* 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003345 hyperglycaemic effect Effects 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 230000000065 osmolyte Effects 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Las formulaciones que contienen insulina NPH son utiles para tratar trastornos hiperglucémicos, tales como la diabetes, en un mamífero que requieredicho tratamiento. Una de tales formulaciones, que se administra preferentemente por víaparenteral, más preferentemente por inyeccion,comprende IGF-I e insulina NPH, en cantidades de entre aproximadamente 1 y 10mg de IGF-I y de aproximadamente 0,2 a 2 mg de insulina NPH en un vehículofarmacéuticamente aceptable. Otra formulacio n deese tipo comprende IGF-I e insulina NPH en una relacion ponderal de insulina NPH a IGF-I deaproximadamente 10:1 a 1:50 (p/p), de aproximadamene 0,05 a 0,3M de un osmolito, de aproximadamente 0,1 a 10mg/ml de un estabilizador, y deaproximadamente 5 a 100 mM de un tampon a un pH de aproximadamente 5 a 7. Otra compsocion adicional comprende insulina NPH en un tampon de sal de ácidoacético.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/696,314 US5783556A (en) | 1996-08-13 | 1996-08-13 | Formulated insulin-containing composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR009066A1 true AR009066A1 (es) | 2000-03-08 |
Family
ID=24796556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970103667A AR009066A1 (es) | 1996-08-13 | 1997-08-12 | Composicion formulada con contenido de insulina |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5783556A (es) |
| EP (2) | EP1114644B1 (es) |
| JP (1) | JP4187075B2 (es) |
| AR (1) | AR009066A1 (es) |
| AT (2) | ATE205722T1 (es) |
| AU (1) | AU731745B2 (es) |
| CA (1) | CA2261799C (es) |
| DE (2) | DE69706872T2 (es) |
| DK (2) | DK0918536T3 (es) |
| ES (2) | ES2162321T3 (es) |
| HK (1) | HK1042229B (es) |
| IL (1) | IL128128A (es) |
| PT (2) | PT1114644E (es) |
| SI (1) | SI1114644T1 (es) |
| WO (1) | WO1998006423A1 (es) |
| ZA (1) | ZA976598B (es) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6428771B1 (en) | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
| US7312196B2 (en) * | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US6410511B2 (en) * | 1997-01-08 | 2002-06-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| AU718500B2 (en) * | 1997-01-23 | 2000-04-13 | Sumitomo Pharmaceuticals Company, Limited | Remedies for diabetes |
| EP1006794B1 (en) * | 1997-03-12 | 2007-11-28 | Robert W. Esmond | A method for treating or preventing alzheimer's disease |
| CA2319195A1 (en) | 1998-02-02 | 1999-08-05 | Trustees Of Tufts College | Method of regulating glucose metabolism, and reagents related thereto |
| US20040058873A1 (en) * | 1998-03-12 | 2004-03-25 | Esmond Robert W. | Method for treating or preventing Alzheimer's disease |
| AU3473999A (en) * | 1998-04-03 | 1999-10-25 | Chiron Corporation | Injectable igf-formulations containing succinate as buffering agent |
| US6436897B2 (en) * | 1998-06-01 | 2002-08-20 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for IGF/IGFBP |
| US6211144B1 (en) * | 1998-10-16 | 2001-04-03 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
| CA2369451C (en) * | 1999-04-08 | 2009-09-22 | Genentech, Inc. | Composition based on oppositely-charged polypeptides |
| WO2001000223A2 (en) * | 1999-06-25 | 2001-01-04 | Minimed Inc. | Multiple agent diabetes therapy |
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| PT1196430E (pt) | 1999-06-29 | 2012-04-18 | Mannkind Corp | Purificação e estabilização de péptidos e proteínas em agentes farmacêuticos |
| US7651703B2 (en) * | 1999-10-15 | 2010-01-26 | Genentech, Inc. | Injection vehicle for polymer-based formulations |
| US7582311B1 (en) | 1999-10-15 | 2009-09-01 | Genentech, Inc. | Injection vehicle for polymer-based formulations |
| WO2002067969A2 (en) | 2001-02-21 | 2002-09-06 | Medtronic Minimed, Inc. | Stabilized insulin formulations |
| DE10114178A1 (de) * | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| SE0101980D0 (sv) * | 2001-06-01 | 2001-06-01 | Astrazeneca Ab | Pharmaceutical combination |
| SE0101982D0 (sv) * | 2001-06-01 | 2001-06-01 | Astrazeneca Ab | Pharmaceutical combination |
| FR2826278B1 (fr) * | 2001-06-20 | 2005-03-25 | Lipha | Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant |
| US6737401B2 (en) * | 2001-06-28 | 2004-05-18 | Metronic Minimed, Inc. | Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom |
| EP2316470A3 (en) * | 2001-11-26 | 2011-08-24 | Trustees Of Tufts College | Peptidomimetic inhibitors of post-proline cleaving enzymes |
| WO2003045228A2 (en) * | 2001-11-26 | 2003-06-05 | Trustees Of Tufts College | Methods for treating autoimmune disorders, and reagents related thereto |
| WO2003080149A2 (en) | 2002-03-20 | 2003-10-02 | Mannkind Corporation | Inhalation apparatus |
| DE10227232A1 (de) * | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
| AU2003303646B2 (en) | 2002-12-31 | 2010-03-04 | Altus Pharmaceuticals Inc. | Human growth hormone crystals and methods for preparing them |
| WO2004078198A1 (en) * | 2003-03-04 | 2004-09-16 | The Technology Development Company Ltd. | Long acting injectable insulin composition and methods of making and using thereof |
| US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
| US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
| US20080090753A1 (en) * | 2004-03-12 | 2008-04-17 | Biodel, Inc. | Rapid Acting Injectable Insulin Compositions |
| US20080096800A1 (en) * | 2004-03-12 | 2008-04-24 | Biodel, Inc. | Rapid mucosal gel or film insulin compositions |
| AU2005222613B2 (en) * | 2004-03-12 | 2009-12-17 | Biodel, Inc. | Rapid acting drug delivery compositions |
| US7713574B2 (en) | 2004-07-13 | 2010-05-11 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US20070045902A1 (en) | 2004-07-13 | 2007-03-01 | Brauker James H | Analyte sensor |
| DE602005024413D1 (de) | 2004-08-20 | 2010-12-09 | Mannkind Corp | Katalyse der diketopiperazinsynthese |
| ES2540886T3 (es) | 2004-08-23 | 2015-07-14 | Mannkind Corporation | Sales de dicetopiperazina para la administración de fármacos |
| US8133178B2 (en) | 2006-02-22 | 2012-03-13 | Dexcom, Inc. | Analyte sensor |
| US20090060861A1 (en) * | 2005-05-25 | 2009-03-05 | Novo Nordisk A/S | Stabilized Polypeptide Formulations |
| CN101180081B (zh) * | 2005-05-25 | 2015-08-26 | 诺沃-诺迪斯克有限公司 | 稳定的多肽制剂 |
| KR101557502B1 (ko) | 2005-09-14 | 2015-10-06 | 맨카인드 코포레이션 | 결정질 미립자 표면에 대한 활성제의 친화력의 증가를기반으로 하는 약물 제제의 방법 |
| US8084420B2 (en) | 2005-09-29 | 2011-12-27 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
| US7713929B2 (en) | 2006-04-12 | 2010-05-11 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
| US20070086952A1 (en) * | 2005-09-29 | 2007-04-19 | Biodel, Inc. | Rapid Acting and Prolonged Acting Inhalable Insulin Preparations |
| AU2007216966C1 (en) | 2006-02-22 | 2014-03-20 | Mannkind Corporation | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
| CA2649109A1 (en) | 2006-04-12 | 2007-10-25 | Biodel, Inc. | Rapid acting and long acting insulin combination formulations |
| US20090147006A1 (en) * | 2007-12-07 | 2009-06-11 | Roche Diagnostics Operations, Inc. | Method and system for event based data comparison |
| FR2925333B1 (fr) * | 2007-12-19 | 2012-04-13 | Farid Bennis | Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives |
| AU2009204309B2 (en) * | 2008-01-04 | 2012-11-22 | Biodel, Inc. | Insulin formulations for insulin release as a function of tissue glucose levels |
| TWI394580B (zh) * | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
| PL2293833T3 (pl) | 2008-06-13 | 2016-08-31 | Mannkind Corp | Inhalator proszkowy i układ do dostarczania leku |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| EP2609954B1 (en) | 2008-06-20 | 2021-12-29 | MannKind Corporation | An interactive apparatus for real-time profiling of inhalation efforts |
| TWI532497B (zh) | 2008-08-11 | 2016-05-11 | 曼凱公司 | 超快起作用胰島素之用途 |
| DK2349324T3 (en) | 2008-10-17 | 2017-12-11 | Sanofi Aventis Deutschland | COMBINATION OF AN INSULIN AND A GLP-1 AGONIST |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| WO2010089706A1 (en) | 2009-02-04 | 2010-08-12 | Ecole Polytechnique Federale De Lausanne (Epfl) | Use of igf-1 and nt-3 in the treatment of x-linked adrenoleukodystrophy |
| US9060927B2 (en) * | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
| EP2405963B1 (en) | 2009-03-11 | 2013-11-06 | MannKind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
| KR20180079458A (ko) | 2009-06-12 | 2018-07-10 | 맨카인드 코포레이션 | 한정된 비표면적을 갖는 디케토피페라진 마이크로입자 |
| WO2011041463A2 (en) | 2009-09-30 | 2011-04-07 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US9016147B2 (en) | 2009-11-03 | 2015-04-28 | Mannkind Corporation | Apparatus and method for simulating inhalation efforts |
| JP5973918B2 (ja) | 2009-11-13 | 2016-08-23 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ｇｌｐ−１アゴニスト及びメチオニンを含む薬学的組成物 |
| KR101836070B1 (ko) | 2009-11-13 | 2018-03-09 | 사노피-아벤티스 도이칠란트 게엠베하 | Ｇｌｐ－１ 작용제, 인슐린 및 메티오닌을 포함하는 약제학적 조성물 |
| CA2801936C (en) | 2010-06-21 | 2021-06-01 | Mannkind Corporation | Dry powder drug delivery system and methods |
| PT2611458T (pt) | 2010-08-30 | 2016-12-16 | Sanofi Aventis Deutschland | Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2 |
| EP2694402B1 (en) | 2011-04-01 | 2017-03-22 | MannKind Corporation | Blister package for pharmaceutical cartridges |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| US9993529B2 (en) | 2011-06-17 | 2018-06-12 | Halozyme, Inc. | Stable formulations of a hyaluronan-degrading enzyme |
| CN108079281A (zh) | 2011-08-29 | 2018-05-29 | 赛诺菲-安万特德国有限公司 | 用于2型糖尿病患者中的血糖控制的药物组合 |
| AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
| EP2776053A1 (en) | 2011-10-24 | 2014-09-17 | MannKind Corporation | Methods and compositions for treating pain |
| AU2013289957B2 (en) | 2012-07-12 | 2017-02-23 | Mannkind Corporation | Dry powder drug delivery systems and methods |
| AR091902A1 (es) * | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
| EP2911690A1 (en) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Inhalable influenza vaccine compositions and methods |
| RU2015130613A (ru) * | 2012-12-26 | 2017-01-31 | Вокхардт Лимитед | Фармацевтическая композиция |
| KR102499439B1 (ko) | 2013-03-15 | 2023-02-13 | 맨카인드 코포레이션 | 미세결정성 디케토피페라진 조성물 및 방법 |
| MX2020009878A (es) | 2013-07-18 | 2022-07-27 | Mannkind Corp | Composiciones farmaceuticas en polvo seco estables al calor y metodos. |
| JP2016530930A (ja) | 2013-08-05 | 2016-10-06 | マンカインド コーポレイション | 通気装置及び方法 |
| SG11201604710XA (en) | 2014-01-09 | 2016-07-28 | Sanofi Sa | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| CN105899191B (zh) * | 2014-01-09 | 2020-06-16 | 赛诺菲 | 胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂 |
| US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| CN107206058A (zh) | 2014-12-12 | 2017-09-26 | 赛诺菲-安万特德国有限公司 | 甘精胰岛素/利西拉来固定比率配制剂 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| EP4228676A1 (en) * | 2020-10-19 | 2023-08-23 | Oak Hill Bio Limited | Compositions suitable for use in neonates |
| DE102021122096A1 (de) * | 2021-08-26 | 2023-03-02 | Forschungsinstitut für Nutztierbiologie | IGF-1, IGFBP-2 und Insulin umfassende Zusammensetzungen und ihre Verwendung |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE95236T1 (de) * | 1983-04-25 | 1993-10-15 | Chiron Corp | Hybrid-dns-synthesis von reifen insulinaehnlichen wachstumsfaktoren. |
| IL71991A (en) * | 1983-06-06 | 1994-05-30 | Genentech Inc | Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes |
| US4988675A (en) * | 1988-02-05 | 1991-01-29 | Ciba-Geigy Corporation | Method for preventing secondary effects |
| US5091173A (en) * | 1989-06-29 | 1992-02-25 | The University Of Dundee | Hair growth composition |
| GB8920381D0 (en) * | 1989-09-08 | 1989-10-25 | Greater Glasgow Health Board | Treatment of insulin-resistant diabetes |
| JPH0818999B2 (ja) * | 1990-01-05 | 1996-02-28 | 藤沢薬品工業株式会社 | インシュリン様成長因子ｉの乾燥製剤 |
| US5126324A (en) * | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
| DK0586589T3 (da) * | 1991-05-24 | 1997-09-22 | Amylin Pharmaceuticals Inc | Amylin- eller amylinanalogpræparat, som eventuelt indeholder insulin, til behandling af anoreksi og beslægtede tilstande |
| US5202119A (en) * | 1991-06-28 | 1993-04-13 | Genentech, Inc. | Method of stimulating immune response |
| JPH0543453A (ja) * | 1991-08-20 | 1993-02-23 | Sumitomo Pharmaceut Co Ltd | 創傷治癒促進用局所用徐放性製剤 |
| HUT67319A (en) * | 1991-08-30 | 1995-03-28 | Life Medical Sciences Inc | Compositions for treating wounds |
| CA2123685C (en) * | 1991-11-25 | 2003-10-07 | Hans-Arne Hansson | Medicament for promoting growth of mammalian nerve |
| DE4208552A1 (de) * | 1992-03-17 | 1993-09-23 | Liedtke Pharmed Gmbh | Topische arzneiformen mit insulin |
| SE9201573D0 (sv) * | 1992-05-19 | 1992-05-19 | Kabi Pharmacia Ab | Use of igf-1 |
| AU674527B2 (en) * | 1992-06-24 | 1997-01-02 | Hot Pepper Wax, Inc. | Organic pesticide |
| WO1994004030A1 (en) * | 1992-08-26 | 1994-03-03 | Celtrix Pharmaceuticals, Inc. | Method for systemic treatment of catabolic conditions and systemic tissue injury |
| JPH08500123A (ja) * | 1993-01-25 | 1996-01-09 | ザ ベス イスラエル ホスピタル アソシエイション | Ｉｇｆ−ｉ感受性細胞のバリヤー特性の修飾方法，診断方法及びスクリーニング方法 |
| AU6093794A (en) * | 1993-01-29 | 1994-08-15 | Synergen, Inc. | Wound healing composition |
| SE9402119D0 (sv) * | 1994-06-16 | 1994-06-16 | Pharmacia Ab | Solution |
| SE9402331D0 (sv) * | 1994-07-01 | 1994-07-01 | Pharmacia Ab | New use |
| SE9402370D0 (sv) * | 1994-07-04 | 1994-07-04 | Pharmacia Ab | Use of IGF-I |
| AUPM678294A0 (en) * | 1994-07-13 | 1994-08-04 | Gropep Pty Ltd | Use of insulin-like growth factor in combination with insulin |
| DK1044015T3 (da) * | 1998-01-09 | 2008-12-08 | Amylin Pharmaceuticals Inc | Formuleringer med amylinagonistpeptider og insulin |
| ATE277630T1 (de) * | 1998-10-16 | 2004-10-15 | Novo Nordisk As | Stabile konzentrierte insulin präparationen zur pulmonaren verabreichung |
| CA2369451C (en) * | 1999-04-08 | 2009-09-22 | Genentech, Inc. | Composition based on oppositely-charged polypeptides |
| WO2001000223A2 (en) * | 1999-06-25 | 2001-01-04 | Minimed Inc. | Multiple agent diabetes therapy |
-
1996
- 1996-08-13 US US08/696,314 patent/US5783556A/en not_active Expired - Lifetime
-
1997
- 1997-07-24 ZA ZA976598A patent/ZA976598B/xx unknown
- 1997-07-31 AT AT97935259T patent/ATE205722T1/de active
- 1997-07-31 AT AT01106315T patent/ATE222120T1/de active
- 1997-07-31 PT PT01106315T patent/PT1114644E/pt unknown
- 1997-07-31 WO PCT/US1997/013566 patent/WO1998006423A1/en active IP Right Grant
- 1997-07-31 DK DK97935259T patent/DK0918536T3/da active
- 1997-07-31 PT PT97935259T patent/PT918536E/pt unknown
- 1997-07-31 ES ES97935259T patent/ES2162321T3/es not_active Expired - Lifetime
- 1997-07-31 AU AU38243/97A patent/AU731745B2/en not_active Expired
- 1997-07-31 DE DE69706872T patent/DE69706872T2/de not_active Expired - Lifetime
- 1997-07-31 EP EP01106315A patent/EP1114644B1/en not_active Expired - Lifetime
- 1997-07-31 ES ES01106315T patent/ES2180523T3/es not_active Expired - Lifetime
- 1997-07-31 IL IL128128A patent/IL128128A/en not_active IP Right Cessation
- 1997-07-31 JP JP50979998A patent/JP4187075B2/ja not_active Expired - Lifetime
- 1997-07-31 DK DK01106315T patent/DK1114644T3/da active
- 1997-07-31 CA CA002261799A patent/CA2261799C/en not_active Expired - Lifetime
- 1997-07-31 SI SI9730387T patent/SI1114644T1/xx unknown
- 1997-07-31 DE DE69714796T patent/DE69714796T2/de not_active Expired - Lifetime
- 1997-07-31 EP EP97935259A patent/EP0918536B1/en not_active Expired - Lifetime
- 1997-08-12 AR ARP970103667A patent/AR009066A1/es active IP Right Grant
-
2002
- 2002-01-10 HK HK02100191.5A patent/HK1042229B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE69714796T2 (de) | 2003-04-03 |
| EP0918536B1 (en) | 2001-09-19 |
| US5783556A (en) | 1998-07-21 |
| PT1114644E (pt) | 2002-12-31 |
| AU3824397A (en) | 1998-03-06 |
| ATE222120T1 (de) | 2002-08-15 |
| CA2261799C (en) | 2009-09-08 |
| DE69714796D1 (de) | 2002-09-19 |
| DK0918536T3 (da) | 2001-12-03 |
| HK1042229B (zh) | 2003-08-15 |
| PT918536E (pt) | 2002-03-28 |
| DK1114644T3 (da) | 2002-11-04 |
| JP4187075B2 (ja) | 2008-11-26 |
| DE69706872D1 (de) | 2001-10-25 |
| EP1114644A1 (en) | 2001-07-11 |
| HK1042229A1 (en) | 2002-08-09 |
| JP2000516229A (ja) | 2000-12-05 |
| WO1998006423A1 (en) | 1998-02-19 |
| EP1114644B1 (en) | 2002-08-14 |
| CA2261799A1 (en) | 1998-02-19 |
| ATE205722T1 (de) | 2001-10-15 |
| ES2180523T3 (es) | 2003-02-16 |
| DE69706872T2 (de) | 2002-04-25 |
| EP0918536A1 (en) | 1999-06-02 |
| IL128128A (en) | 2007-06-17 |
| SI1114644T1 (en) | 2002-12-31 |
| ES2162321T3 (es) | 2001-12-16 |
| AU731745B2 (en) | 2001-04-05 |
| ZA976598B (en) | 1999-02-17 |
| IL128128A0 (en) | 1999-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR009066A1 (es) | Composicion formulada con contenido de insulina | |
| KR100221123B1 (ko) | 안정화된 고나도트로핀을 함유하는 제제 | |
| CR6035A (es) | Jarabe antihistaminico estabilizado | |
| KR890011837A (ko) | 디데하이드로 비타민 d₃유도체 | |
| CA2042973A1 (en) | Tgf-beta compositions | |
| AR006598A1 (es) | "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación" | |
| RU2001111880A (ru) | Композиции для перорального введения, содержащие луфенурон и нитенпирам, для борьбы с блохами | |
| ES2753822T3 (es) | Combinación unitaria de FSH y hCG | |
| ES2263853T3 (es) | Uso de prostaglandina a o sus derivados para el tratamiento de la psoriasis. | |
| BRPI0709985A2 (pt) | composição de brimonidina e timolol | |
| AR017973A1 (es) | Formulacion farmaceutica isotonica, uso de dicha formulacion en la preparacion de un medicamento para uso en la terapia de una enfermedad autoinmune,y metodo para mejorar el almacenamiento de un anticuerpo | |
| Collu et al. | Endocrine effects of chronic administration of psychoactive drugs to prepuberal male rats. I: Δ9-tetrahydrocannabinol | |
| EP0455725A1 (en) | PHARMACEUTICAL FORMULATION OF PLASMINOGEN ACTIVATOR PROTEINS. | |
| US4241051A (en) | Calcitonin | |
| Chen et al. | The combination of twice daily luteinizing hormone-releasing factor administration and renal pituitary homografts restores normal reproductive organ size in male hamsters with pineal-mediated gonadal atrophy | |
| US5964224A (en) | Method for treating amyotrophic lateral sclerosis and a therapeutic agent therefor | |
| WO1996001634B1 (en) | Long-acting oxytetracycline composition | |
| KR950701922A (ko) | 치환된 트리아졸의 설페이트 염, 이를 포함하는 약제학적 조성물 및 치료요법에서의 이의 용도(The sulphate salt of a substituted triazole, pharmaceutical compositions thereof and their use in therapy) | |
| ES2105923B1 (es) | Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv). | |
| RU2000116647A (ru) | Однодозовый шприц, содержащий композицию лиофилизованного белка, для введения объема менее, чем 0,5 мл | |
| CO5021217A1 (es) | Composiciones estables de mitoxantrona, procedimietno para prepararlas; utilizacion de dichas composiciones y medica- mentos que incluyen dichas soluciones para el tratamiento de enfermedades cancerosas | |
| DK1069912T3 (da) | Injicerbare IGF-formuleringer, der indeholder succinat som puffermiddel | |
| EA199900510A1 (ru) | Инъекционное лекарственное средство "цитофлавин", обладающее цитопротекторным действием | |
| JPS6360940A (ja) | 白内障の予防または治療剤 | |
| DE69627706D1 (de) | Wässrige zusammensetzung mit verzögerter freisetzung, enthaltend rinderwachstumshormon-freisetzungsfaktor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |